MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma-Reference-Cited by-同舟云学术

MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma

Published:2018-07-04 Issue:448 Volume:10 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Yohe Marielle E.¹²^ORCID,Gryder Berkley E.¹^ORCID,Shern Jack F.²,Song Young K.¹,Chou Hsien-Chao¹,Sindiri Sivasish¹,Mendoza Arnulfo²,Patidar Rajesh¹,Zhang Xiaohu³,Guha Rajarashi³^ORCID,Butcher Donna⁴^ORCID,Isanogle Kristine A.⁵,Robinson Christina M.⁵,Luo Xiaoling⁶,Chen Jin-Qiu⁶,Walton Ashley¹,Awasthi Parirokh⁵^ORCID,Edmondson Elijah F.⁴^ORCID,Difilippantonio Simone⁵,Wei Jun S.¹^ORCID,Zhao Keji⁷,Ferrer Marc³,Thomas Craig J.³,Khan Javed¹^ORCID

Affiliation:

1. Oncogenomics Section, Genetics Branch, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD 20892, USA.

2. Pediatric Oncology Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.

3. Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Bethesda, MD 20892, USA.

4. Pathology/Histotechnology Laboratory, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, NIH, Frederick, MD 21702, USA.

5. Laboratory Animal Sciences Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, NIH, Frederick, MD 21701, USA.

6. Collaborative Protein Technology Resource, National Cancer Institute, NIH, Bethesda, MD 20892, USA.

7. Systems Biology Center, National Heart Lung and Blood Institute, NIH, Bethesda, MD 20892, USA.

Abstract

MEK inhibition decreases cell viability and induces differentiation in RAS-driven rhabdomyosarcoma via an epigenetic mechanism.

Funder

Alex’s Lemonade Stand Foundation for Childhood Cancer

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference89 articles.

1. A Comprehensive Survey of Ras Mutations in Cancer

2. Drugging the undruggable RAS: Mission Possible?

3. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

4. Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma

5. Mutant RAS inhibits neutrophil but not macrophage differentiation and allows continued growth of neutrophil precursors

Cited by 115 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preclinical evidence for employing MEK inhibition in NRAS mutated pediatric gastroenteropancreatic neuroendocrine-like tumors;Translational Oncology;2024-09

2. Insights into the epitranscriptomic role of N6-methyladenosine on aging skeletal muscle;Biomedicine & Pharmacotherapy;2024-08

3. Tongue orthotopic xenografts to study fusion-negative rhabdomyosarcoma invasion and metastasis in live animals;Cell Reports Methods;2024-07

4. Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma;Cancers;2024-06-25

5. Epigenetic determinants of fusion-driven sarcomas: paradigms and challenges;Frontiers in Cell and Developmental Biology;2024-06-14